Search Results - "Fang, Bruno S."

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Prognostic Impact of Missed Chemotherapy Doses During Chemoradiation Therapy for Non-Small Cell Lung Cancer by Deek, Matthew P, Kim, Sinae, Ahmed, Inaya, Fang, Bruno S, Zou, Wei, Malhotra, Jyoti, Aisner, Joseph, Jabbour, Salma K

    Published in American journal of clinical oncology (01-04-2018)
    “…The aim of this study is to investigate the impact of missed chemotherapy administrations (MCA) on the prognosis of non-small cell lung cancer (NSCLC) patients…”
    Get full text
    Journal Article
  2. 2

    BRCA1-Associated Growth Arrest Is RB-Dependent by Aprelikova, Olga N., Fang, Bruno S., Meissner, Eric G., Cotter, Shane, Campbell, Mel, Kuthiala, Aalok, Bessho, Mika, Jensen, Roy A., Liu, Edison T.

    “…BRCA1 is a susceptibility gene for breast and ovarian cancer with growth-inhibitory activity for which the mechanism of action remains unclear. When introduced…”
    Get full text
    Journal Article
  3. 3

    Ibrutinib Dose Reductions and Discontinuations Patterns Among Patients with Chronic Lymphocytic Leukemia from a Large Community Medical Oncology Practice by Du, Senxi, Fang, Bruno S., Yeung, Percy, Peng, Eileen, Keck, Marisa

    Published in Blood (05-11-2020)
    “…Introduction: Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of first-line (1L) and relapsed/refractory (R/R) chronic lymphocytic…”
    Get full text
    Journal Article
  4. 4

    Dose Reductions and Discontinuations with Chronic Lymphocytic Leukemia (CLL) Patients Receiving Ibrutinib in Community and Academic Settings by Hou, Jing-Zhou, Ryan, Kellie, Du, Senxi, Fang, Bruno S., Marks, Stanley M., Page, Ray, Peng, Eileen, Szymanski, Keith, Winters, Sharon, Le, Hannah

    Published in Blood (05-11-2020)
    “…Introduction: Since its approval in 2014, ibrutinib has replaced chemotherapy to become a preferred therapy for CLL patients. Real-world studies of ibrutinib…”
    Get full text
    Journal Article
  5. 5

    Report of a factor VIII inhibitor in a patient with autoimmune lymphoproliferative syndrome by Fang, Bruno S., Sneller, Michael C., Straus, Stephen E., Frenkel, Lawrence, Dale, Janet K., Rick, Margaret E.

    Published in American journal of hematology (01-07-2000)
    “…The occurrence of factor VIII inhibitors in non‐hemophilic patients is a rare event with a potentially lethal outcome. Despite its infrequent occurrence, the…”
    Get full text
    Journal Article